Background竊� Statins has been regarded as a long-term strategy to reduce cardiovascular events in patients with stable coronary artery disease. Further, the Pitavastatin (Livalo) is a potent lipophilic statin and may play an important role in acute myocardial infarction (AMI) setting by not only reducing LDL-cholesterol, but also through the pleiotrophic effects.Method: The study originated from the Livalo AMI study (LAMIS), which exclusively used Pitavastatin (Livalo) 2mg/day as sole statin therapy from the presentation time and the Korea AMI Registry (KAMIR), which consisted of 2530 consecutive AMI patients (pts) from April 2007 to March 25, 2009. We compared the clinical outcomes using propensity score adjustment among the AMI pts treated with Pitavastatin (Livalo, n=601), overall statins from KAMIR (n=1461) and without statin treatment from KAMIR (n=468) up to 12 months.Results: Patients in Livalo group were younger and successful PCI rate and ejection fraction (EF) was higher than those of no statin group (p<0.05). Pitavastatin (ORunadjusted: 0.560, 95% CI: 0.360-0.873, P=0.010, ORadjusted by propensity score: 0.200, 95% CI: 0.065-0.613, P= 0.005) and overall statin administration (OR: 0.812, 95% CI: 0.550-1.199, P=0.295) was associated with less incidence of MACE at 12 months compared with the AMI pts without any statin therapy ( Figure ).Conclusion: Routine administration of 2mg Pitavastatin daily or overall statins in AMI pts showed similarly better 12-month clinical outcomes compared with AMI patients without statin treatment.